An Open-label Study To Evaluate The Safety And Pharmacokinetics Of Pf-06412528 In Children 7-17 Years For The Treatment Of Moderate-to-severe Pain
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Morphine/naltrexone (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Pfizer
- 04 Jan 2017 Planned End Date changed from 1 Jul 2019 to 1 Sep 2018.
- 04 Jan 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2018.
- 26 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.